Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy

  • Authors:
    • Susumu Saigusa
    • Yasuhiko Mohri
    • Masaki Ohi
    • Yuji Toiyama
    • Yoshito Ishino
    • Yoshinaga Okugawa
    • Koji Tanaka
    • Yasuhiro Inoue
    • Masato Kusunoki
  • View Affiliations

  • Published online on: August 2, 2011     https://doi.org/10.3892/or.2011.1408
  • Pages: 1069-1074
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Neoadjuvant chemo-radiotherapy (CRT) followed by surgery are the standard approaches for locally advanced esophageal cancer. However, the overall cure rate is very low. The aim of this preliminary study was to evaluate the expression of podoplanin and SOX2 known as stemness markers for esophageal squamous cell carcinoma (ESCC) and their association with clinical outcome. We obtained a total of 20 specimens from patients with ESCC who underwent neoadjuvant CRT (30-40 Gy; 5-fluorouracil plus cisplatin) followed by surgery. Podoplanin and SOX2 expression was evaluated using immunohistochemistry and the association of their expressions with clinicopathological variables was investigated. Podoplanin and SOX2 staining was detected not only in residual cancer cells, but also in the basal layer of adjacent normal mucosa after neoadjuvant CRT. High expression of podoplanin was correlated with lymph node metastasis, advanced postoperative stage and vascular invasion (P<0.05), while, high expression of SOX2 was correlated with lymphatic, vascular invasion, poor differentiated tumor and incomplete resection (P<0.05). High expression of podoplanin was significantly associated with poor overall survival (P<0.05). In conclusion, the expression levels of podoplanin and SOX2 expression may be useful prognostic markers for ESCC treated with neoadjuvant CRT.

Related Articles

Journal Cover

November 2011
Volume 26 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Saigusa S, Mohri Y, Ohi M, Toiyama Y, Ishino Y, Okugawa Y, Tanaka K, Inoue Y and Kusunoki M: Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy. Oncol Rep 26: 1069-1074, 2011
APA
Saigusa, S., Mohri, Y., Ohi, M., Toiyama, Y., Ishino, Y., Okugawa, Y. ... Kusunoki, M. (2011). Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy. Oncology Reports, 26, 1069-1074. https://doi.org/10.3892/or.2011.1408
MLA
Saigusa, S., Mohri, Y., Ohi, M., Toiyama, Y., Ishino, Y., Okugawa, Y., Tanaka, K., Inoue, Y., Kusunoki, M."Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy". Oncology Reports 26.5 (2011): 1069-1074.
Chicago
Saigusa, S., Mohri, Y., Ohi, M., Toiyama, Y., Ishino, Y., Okugawa, Y., Tanaka, K., Inoue, Y., Kusunoki, M."Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy". Oncology Reports 26, no. 5 (2011): 1069-1074. https://doi.org/10.3892/or.2011.1408